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INTRODUCTION

Chronic kidney disease (CKD) is becoming increasingly common, with an estimated
incidence of 10% in Australian adults, and more than 40% in people aged 75 and over1.
Progression of CKD leads to end stage kidney disease (ESKD) and ultimately the need for renal
replacement therapy (RRT), with an incidence of 124 per million population in Australia in 20172.
Peritoneal dialysis (PD) is one modality of RRT, accounting for around 19% of all Australian
dialysis patients3. Compared to haemodialysis, PD is often the preferred modality due to
preservation of residual renal function, which may mitigate cardiovascular risk; improved early
survival as well as convenience and flexibility for patients such as the ability to travel4. The main
complication of PD is peritonitis, with an incidence of 31 per 100 patient years in Australian PD
patients3.

CKD is associated with up to a 20-fold increase in risk of cardiovascular death compared to
patients without CKD5. In Australian PD patient’s, cardiovascular disease (CVD) is the leading
cause of mortality accounting for up to 35% of deaths6. While there is a high prevalence of
cardiovascular risk factors in patients with CKD, this does not completely explain the excessive
cardiovascular risk experienced by this population5,7-8. This may be attributed to the important
biochemical and physiological changes associated with CKD including; abnormal calcium and
phosphate metabolism, malnutrition, inflammation, enhanced coagulability, anaemia, uraemic
toxicity, fluid overload, vascular calcification and endothelial dysfunction5,7,9-10. In the PD

population, high glucose concentrations in PD fluid may contribute to dyslipidaemia and insulin
resistance5 and exposure to bio-incompatible PD fluid and glucose degradation products (GDPs)
may contribute to a state of chronic inflammation, all of which increase cardiovascular risk7,10.
Furthermore, PD fluid and GDPs lead to the accumulation of reactive oxygen species which are
thought to play a key role in endothelial damage and atherosclerosis11.

It is well recognised that patients with CKD are at increased risk of infection compared to
those without CKD8,

12-13,

with more severe infective episodes12 and an increased associated

mortality12,14. This may be due to impaired immunity, reduced vaccination responsiveness,
significant comorbidities, and frequent exposure to healthcare facilities13. An association between
infection and CVD has been demonstrated in the general (non-CKD) population15-16 and in nondialysis CKD populations8.

In the haemodialysis population, bacteraemia or septicaemia is

associated with a 78% increase in risk of myocardial infarction17, while infection related
hospitalisations in older dialysis patients increase the risk of cardiovascular events in the following
30 days by 25%18. Moreover, PD patients are at higher risk of death from CVD after the first year of
treatment compared to haemodialysis patients and this is presumed, in part, to be due to increased
infectious episodes over time5.

Peritonitis has been associated with increased risk of mortality, with one Australian study
demonstrating a 19% mortality in PD patients within 30 days of a peritonitis episode19. It is
hypothesized that systemic inflammation resulting from peritonitis may predispose patients to
cardiovascular events12, however there is a paucity of research examining this association in the
PD population. While a recent study established an association between peritonitis and late
cardiovascular mortality in PD patients7, no studies have examined the association between
peritonitis and all cardiovascular events in this population. We aimed to examine if peritonitis is a

risk factor for all cardiovascular events in PD patients. We hypothesised that an episode of
peritonitis increases the risk of future cardiovascular events in patients undertaking PD.

MATERIALS AND METHODS

We conducted a retrospective cohort study of PD patients from one health district in New
South Wales, Australia. We included adults, aged 18 years and over, who commenced PD from
2001 to 2015. Patients were excluded if they were on PD for < 3 months, previously had a renal
transplant, or underwent haemodialysis previously for ≥6 months, had recovered their renal
function, or had commenced PD in another area health service (Figure 1). At the study design
phase we calculated the sample size required. For a power of 0.8 at an alpha level of 0.05 we
anticipated that the Hazard Ratio for cardiovascular events from infection to be 2.0 (based on
studies for chronic kidney disease showing a HR of 1.8- 3.0)8. We also anticipated for the exposure
(peritonitis) rate based on the ANZDATA to be 60%3 and the event rate (cardiovascular events) to
be 50%. Assuming a drop-out rate of 15% the sample size calculated was 225. This study was
approved by the University of Wollongong and Illawarra Shoalhaven Local Health District Health
and Medical Human Research Ethics Committee (2017/266).

Baseline sociodemographic, laboratory and clinical data was obtained from the Australian
and New Zealand Dialysis and Transplant (ANZDATA) registry. Data included gender, age,
ethnicity, primary renal disease, height and weight (used to calculate Body Mass Index),
comorbidities and smoking status at commencement of RRT. Comorbidities included chronic lung
disease, coronary artery disease, peripheral vascular disease, cerebrovascular disease, diabetes
and any diagnosis of malignancy. Baseline laboratory results included creatinine (mmol/L),
uncorrected calcium (mmol/L), phosphate (mmol/L) and haemoglobin (g/L). Primary renal disease
causing ESKD was classified as diabetes, hypertension, glomerulonephritis, cystic, or other renal
disease. Peritonitis episode data, relocation data, transition between dialysis types, and cause of

death were also obtained from the ANZDATA registry which captures this information in real time.
As part of this study, we included all peritonitis events prior to cardiovascular events.

The primary outcome was any cardiovascular event, defined as a composite of
hospitalization for cardiovascular ischaemia or infarction, unstable angina, congestive cardiac
failure, ischaemic stroke or transient ischaemic attack; and cardiovascular death. Cardiovascular
death was defined as death from cardiac arrest of unknown cause, death from pulmonary oedema,
death from myocardial ischemia or infarction, and death from cerebrovascular event.
Cardiovascular event data was obtained from the ANZDATA registry and from International
Statistical Classification of Disease and Related Health Problems 10th revision (ICD-10) coding and
procedure block numbers using the Australian Classification of Health Interventions (ACHI) codes.
Data linkage was facilitated by the Centre for Health Research Illawarra Shoalhaven Population
(CHRISP). The ICD-10 codes G45.9 (Transient cerebral ischaemic attack, unspecified), I20.0
(Unstable angina), I21 (Acute myocardial infarction), I22 (Subsequent myocardial infarction), I46
(Cardiac arrest), I50 (Heart failure) and I63.9 (Cerebral infarction, unspecified) were used to
identify inpatient cardiovascular events. ACHI codes 667 (Cardiac Catheterisation), 668 (Coronary
angiography), 670 (Transluminal coronary angioplasty), 671 (Transluminal coronary angioplasty
with stenting), and 672-679 (Coronary artery bypass) were also used. Procedure codes were used
to identify admissions, however an intervention alone in the absence of a cardiovascular event as
defined above was not included as an outcome.

Patients were censored after their first cardiovascular event, or at time of death from noncardiac cause, transfer to another NSW health district for more than 30 days or at the end of the
study period (31st December 2015). Categorical data, expressed using frequency (%), was
examined by Chi-Square tests. Continuous data was expressed as medians with interquartile

ranges (IQR) [25th -75th percentile] or mean with standard deviation (SD) and compared by Mann
Whitney or Independent samples t-test as appropriate. Cox regression models were used to
estimate crude hazard ratios (HR) with 95% confidence intervals (95% CI) for cardiovascular
events. Time-dependent covariate analysis using Cox proportional models were used to determine
adjusted HR with 95% CI. The models accounted for a time dependent covariate from date of
commencing PD as the start of follow up time until the first peritonitis episode. Covariate selection
for the final model was based on univariate significance, plausible confounders, established risk
factors and a backwards stepwise model. Statistical analysis was performed using SPSS version
23.0.

RESULTS

We identified 262 patients who commenced PD between 2001 and2015, 51 patients were
excluded (Figure 1). We included a total of 211 patients in the analysis with a median follow up
time of 3.5 years (IQR 1.4 – 6.0 years). The study population had a median age of 66 years (IQR
54.5 - 74.5 years), was predominantly male (64.0%), Caucasian (94.3%), former smokers (46.9%)
and overweight with a mean body mass index (BMI) of 28 kg/m2 (SD 5.1 kg/m2) (Table 1). The
most common cause for ESKD was glomerulonephritis (28.9%), followed by diabetes (26.1%).
There was a high prevalence of diabetes (37.9%) and cardiovascular disease (34.1%) at time of
commencement of RRT.

Of the 211 patients, 114 (54%) experienced a peritonitis event, with a median time to
peritonitis from commencement of RRT of 9.6 months (IQR 4.4-20.8 months). Females were more
likely to have peritonitis compared to males (64.5% v 48.1%, p=0.02). In our cohort, 97 patients
(46%) did not experience peritonitis during the follow up period while 49 patients (23.2%)
experienced 1 episode of peritonitis and 65 patients (30.8%) experienced 2 or more peritonitis
episodes during the follow up period.

CARDIOVASCULAR EVENTS

A total of 65 (30.8%) patients experienced a cardiovascular event. Total cardiovascular
events included death from cardiac causes (32.3%), myocardial infarction (24.6%), unstable
angina (13.8%), transient ischaemic attack (9.2%), cerebrovascular event (9.2%), death from
cerebrovascular event (6.2%) and heart failure (4.6%). The median time from commencement of
PD to cardiovascular event was 30 months (IQR 15-69.4 months). In our cohort, 35 patients

(16.1%) experienced a cardiovascular event after a peritonitis episode, with a median time
from peritonitis episode to cardiovascular event of 2.4 months (IQR 1.1-4.6 months). Risk
factors for a cardiovascular event included cerebrovascular disease (HR 2.72, 95%CI 1.365.47, p=0.005), diabetes (HR 2.41, 95%CI 1.47-3.96, p=0.001) and pre-existing coronary
artery disease at commencement of RRT (HR 1.67, 95%CI 1.01-2.77, p=0.047). Older age
increased the risk of cardiovascular events (HR 1.03, 95%CI 1.01-1.06, p=0.002) which
was augmented when age was over 65 (HR 2.02, 95% CI 1.21-3.38, p=0.007) (Table 2).

ASSOCIATION OF PERITONITIS WITH CARDIOVASCULAR EVENTS

Of the 65 patients who experienced a cardiovascular event, 35 (53.8%) had a
preceding episode of peritonitis and 30 (46.2%) did not. There was no evidence that
patients with a peritonitis episode had an increased risk of cardiovascular events, when
compared to patients with no peritonitis episode (30.7% vs 30.9 %, p=0.97). Time
dependent covariate analysis showed a similar result (HR 1.37 95%CI 0.81-2.32, p=0.24).
After accounting for age, cerebrovascular disease, diabetes and existing coronary artery
disease, the risk of cardiovascular events from peritonitis remained 1.32 (95%CI 0.78-2.23,
p=0.30).

DISCUSSION

This is the first study to examine peritonitis as a risk factor for all cardiovascular events, in
addition to cardiovascular mortality. In our cohort, a large proportion (54%) of patients experienced
at least one episode of peritonitis, with 31% of patients experiencing a cardiovascular event.
Similar to previously established risk factors, we found that a diagnosis of cerebrovascular disease,
diabetes and coronary artery disease at the time of commencing RRT, increased the risk of
cardiovascular events 2.72, 2.41 and 1.67-fold respectively. Older age also increased the risk of
cardiovascular events. However, we did not find an increased risk of cardiovascular events
following an episode of peritonitis.

Current theory indicates that peritonitis may predispose patients to cardiovascular events
through systemic inflammation and direct inflammatory effects on pre-existing coronary artery
atherosclerotic plaques12,19-20. CKD patients have accelerated cardiovascular disease from multiple
factors including oxidative stress, uraemia, fluid overload and chronic inflammation7-8, and
therefore are likely to have underlying atherosclerotic lesions. Haemodynamic changes including
tachycardia and hypotension in the setting of infection can result in demand ischaemia in the
context of pre-existing coronary artery lesions15-16,20. Concurrent endothelial dysfunction leading to
coronary vasoconstriction and increased direct inflammatory activity within the atherosclerotic
lesions, can also lead to plaque rupture10,15-16,20. Systemic inflammatory responses with production
of cytokines, prothrombotic factors, and vasoactive molecules contribute to thrombus formation10,1516,20.

Transient peritoneal membrane changes associated with PD peritonitis may also allow

diffusion of inflammatory cytokines into the blood leading to systemic inflammation which persists
even once the local peritoneal infection settles7.

Infection and cardiovascular risk in the CKD and non-CKD population is now an established
association7-8,15-16. In the CKD population, a prospective cohort study, demonstrated any infection
increased the risk of cardiovascular ischaemia, congestive heart failure and mortality by 1.8, 3.2
and 3.4 times respectively8. These findings can be extended to the dialysis population where an
infection-related hospitalization increases the risk of cardiovascular events by 18%18 and an
episode of bacteraemia increases the risk of congestive cardiac failure, myocardial infarction and
stroke by 1.65, 1.78 and 2.04-fold respectively17.

Our findings are contrary to limited evidence in the literature which suggest that PD
peritonitis is associated with increased cardiovascular mortality. A recent study examining a
Brazilian cohort of PD patients suggested peritonitis was associated with a 22% increased risk of
cardiovascular mortality7. However, the study was limited to cardiovascular mortality only, while
we attempted to capture all cardiovascular events. This study also had a significantly lower
peritonitis frequency (26%) compared to other studies including; a single centre Dutch Study with a
peritonitis frequency of 72%21, an Australian study with a frequency of 56%19, as well as our study
(54%). An ANZDATA study also demonstrated an increased risk of mortality, with 19% of PD
patients dying after an episode of peritonitis within the preceding 30 days, with patients dying of
vascular disease (cardiovascular, cerebrovascular or peripheral vascular disease) being 3.4 times
more likely to have had peritonitis in the preceding 30 days19. Despite this the median time from
peritonitis to death was 247 days (IQR 64-552)19, suggesting the method of case-crossover design
may not have completely examined the long-term impact infection may have on cardiovascular
risk.

There are a number of reasons for our unexpected findings. Our study was a retrospective
analysis utilising records from a single health district. This resulted in a modest sample size which

may have underpowered our study for a statistically significant result. There is also the possibility
that the effect of peritonitis, , as a risk factor for cardiovascular events is attenuated given
emphasis on rapid recognition and early initiation of antibiotics22. Previous studies examining the
association between infection and cardiovascular events in the CKD population relied on
established infection, often requiring hospitalisation or the presence of a positive blood culture8,1718.

A reduction in the severity of the infection episode by rapid recognition and treatment may

mitigate the severe inflammatory response and haemodynamic changes attenuating the risk of
cardiovascular events15-16,20.

However larger studies are required to further examine this

association.

The main strength of this study was the use of a national registry (ANZDATA) with
standardised data collection, as well as the Centre for Health Research Illawarra Shoalhaven
Population’s (CHRISP) data-linkage capacity which facilitated capturing event data. We were also
the first, to the best of our knowledge, to examine PD peritonitis as a risk factor for all
cardiovascular events including cardiovascular mortality. In addition to these strengths, our study
also had some limitations which need to be acknowledged. The ANZDATA registry is a voluntary,
clinician driven registry with no external examination of data accuracy or requirement for
standardized definitions of diagnoses, including peritonitis episodes. Information regarding PD
patients may be missing from the database (e.g. peritonitis episodes, comorbidities) and inaccurate
information may have been entered (e.g. cause of death, date of peritonitis episode). The
ANZDATA database does not provide information on the severity of infection including markers of
inflammation e.g. C-reactive protein, or other risk factors for cardiovascular disease including
hypertension, dyslipidaemia and glycaemic control, residual urine output, dialysis adequacy or
patient compliance; which may result in unidentified associations. Lack of data on the use of
cardioprotective medication including ACE inhibitor, angiotensin receptor antagonists and HMG-

CoA reductase inhibitors was also a limitation. The use of ICD-10 and ACHI coding to identify
cardiovascular events and procedures, rather than clinical data, may have also led to
underestimation of the event rate. However, these limitations are inherent to all studies relying on
registries (5, 18-19). As discussed above our study may also be underpowered. However, given
the retrospective design and reliance on registry data it would not be possible to recruit more
patients. Finally, we did not account for other intercurrent infections (e.g. blood stream infections or
pneumonia) which may have influenced the results.

ACKNOWLEDGEMENTS
The authors acknowledge the CHRISP research partnership established between the
Illawarra Shoalhaven Local Health District (ISLHD) and the University of Wollongong, and ISLHD
for funding support and as the source of data used in this study. We acknowledge the Australian
and New Zealand Dialysis and Transplant registry (ANZDATA) for assisting with the data
acquisition, as well as all of the contributors who voluntarily provide information to the registry.

CONCLUSIONS

Infection is associated with cardiovascular risk, and the risk of infection in CKD remains
higher than the general population. Despite this, our study did not find evidence of an association
between peritonitis and risk of cardiovascular events. This may be due to the modest size of our
study. However, it is possible that rapid recognition and treatment of peritonitis may mitigate this
risk. Larger studies are required to further examine this important association.
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FIGURE LEGENDS

Figure 1: Study population including reasons for exclusion
PD=peritoneal dialysis

TABLES
Table 1: Baseline characteristics stratified by peritonitis versus no peritonitis group
Peritonitis
Variable

Overall

Yes

No

211

114 (54.0)

97 (45.8)

Age, years (IQR)

66.30 (54.49- 74.45)

66.74 (56.25 -74.07)

65.45 (51.48 - 75.35)

0.7

Age ≥ 65, n (%)

111 (52.6)

62 (54.4)

49 (50.5)

0.6

Male, n (%)

135 (64.0)

65 (57.0)

70 (72.2)

0.02

Caucasian, n (%)

199 (94.3)

105 (92.1)

94 (96.9)

0.1

BMI, kg/m (SD)

28.1 (5.1)

28.4 (5.4)

27.7 (4.9)

0.4

<25, n (%)

60 (28.6)

31 (27.4)

29 (29.9)

0.2

25-29.9, n (%)

85 (40.5)

41 (36.3)

44 (45.4)

≥30, n (%)

65 (31.0)

41 (36.3)

24 (24.7)

Diabetes

55(26.1)

26 (22.8)

29 (29.9)

HTN

33 (15.6)

20 (17.5)

13 (13.4)

GN

61 (28.9)

35 (30.7)

26 (26.8)

Cystic

14 (6.6)

5 (4.4)

9 (9.3)

Other

48 (22.7)

28 (24.6)

20 (20.6)

590 (469.0-744.0)

604.5 (475.0-778.5)

575 (449.0-736.5)

0.6

2.31 (0.43)

2.28 (0.19)

2.33 (0.58)

0.4

1.68 (0.50)

1.65 (0.47)

1.70 (0.53)

0.6

115.6 (15.59)

114.3 (14.95)

117.08 (16.24)

0.2

Current

26 (12.3)

13 (11.4)

13 (13.4)

0.6

Former

99 (46.9)

57 (50.0)

42 (43.3)

Never

86 (40.8)

44 (38.6)

42 (43.3)

17 (8.1)

8 (7.0)

9 (9.3)

0.5

72 (34.1)

36 (31.6)

36 (37.1)

0.4

40 (19.0)

19 (16.7)

21 (21.6)

0.4

N (%)

2

p value

Kidney disease, n (%)

Creatinine, µmol/l (IQR)
Calcium (n=169), mmol/l
(SD)
Phosphate (n= 169),
mmol/l (SD)
Haemoglobin (n= 205), g/l
(SD)

0.4

Smoking, n (%)

Chronic Lung disease, n
(%)
Coronary artery disease, n
(%)
Peripheral vascular

disease, n (%)
Cerebrovascular disease,

27 (12.8)

15 (13.2)

12 (12.4)

0.9

Diabetes, n (%)

80 (37.9)

43 (37.7)

37 (38.1)

0.9

Cancer (n=219), n (%)

65 (31.1)

37 (32.7)

28 (29.2)

0.6

n (%)

Continuous variables are expressed as mean (SD) or median (IQR). BMI=Body Mass Index.

Table 2: Univariate Cox Regression analysis for hazard ratio of cardiovascular event
Variable

Hazard Ratio (HR) [95% CI]

p value

Age (years)

1.03 [1.01, 1.06]

0.002

Age ≥ 65 (years)

2.02 [1.21, 3.38]

0.007

Male

0.92 [0.56,1.51]

0.73

Reference

0.48

BMI (<25kg/m2 ref)
<25
25-29.9

0.74 [0.42. 1.33]

≥30

0.71 [0.38, 1.31]

Creatinine mmol/L

0.99 [0.99, 1.00]

0.17

Calcium mmol/L

0.67 [0.14, 3.09]

0.6

Phosphate mmol/L

0.95 [0.52, 1.75]

0.88

Haemoglobin g/L

1.00 [0.98, 1.02]

0.74

Chronic lung disease

1.26 [0.54, 2.92]

0.6

Coronary artery disease

1.67 [1.01, 2.77]

0.047

Peripheral vascular disease

1.64 [0.92, 2.93]

0.096

Cerebrovascular disease

2.72 [1.36, 5.47]

0.005

Diabetes Mellitus

2.41 [1.47, 3.96]

0.001

Cancer

0.74 [0.43, 1.27]

0.27

95% CI= 95% confidence interval, BMI = body mass index.
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